Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
In recent years, radioimmunotherapy (RIT) with beta(-) particle emitting radionuclides targeting the CD20 antigen on B cells in the treatment of non-Hodgkin's lymphoma has provided the most compelling human clinical data for the success of RIT. CD19, like CD20, is an antigen expressed on the surface of cells of the B lineage, and CD19 may provide an alternative target for radioimmunotherapy of B cell neoplasms. CD19 has been largely overlooked as a target for conventional 131I RIT, because the antigen rapidly internalizes upon binding of antibody, resulting in catabolism and significant release of 131I. Such modulation may be an advantage to RIT with radiometals such as 90Y, 177Lu, 213Bi and 225Ac. Herein, we have compared beta(-) particle RIT with antibodies targeting either CD19 or CD20. The anti-CD19 and anti-CD20 antibodies, B4 or C2B8, respectively, were appended with the SCN-CHX-A''-DTPA bifunctional chelating agent and labeled with 90Y. In the tumor model used, there were three times as many CD20 target sites on lymphoma cells as compared to CD19 sites (62000 vs 20000 binding sites, respectively). We compared the efficacy of the 90Y-labeled antibodies to reduce lymphoma in a nude mouse xenograft solid tumor model, after measurable lymphoma appeared. Reduction in tumor size began at day 3 in all three 90Y-treated groups, but tumor began to recur in many animals 9 days after the treatments. There was one cure in each specific treatment group. In contrast, the tumor in the two control groups showed no regression. There was a significant prolongation of median survival time from xenograft (P < 0.0001) in all the 90Y-labeled antibody construct-treated groups (32 days for 0.15 mCi 90Y-B4; 26 days for 0.20 mCi 90Y-C2B8, and 23 days for 0.15 mCi 90Y-C2B8) in comparison to the two control groups (11 days for 0.02 mg of C2B8 and 9 days for untreated growth controls). Specificity of the radioimmunotherapy was also shown. In conclusion, 90Y-labeled anti-CD19 antibody has efficacy comparable to 90Y-labeled anti-CD20 antibody in the treatment of mice bearing human lymphoma xenografts. These data suggest that CD19-targeted RIT merits further study.
Ma
D
D
Department of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
McDevitt
M R
MR
Barendswaard
E
E
Lai
L
L
Curcio
M J
MJ
Pellegrini
V
V
Brechbiel
M W
MW
Scheinberg
D A
DA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000915:Antibody Affinity; D018941:Antigens, CD19 / Q000276:immunology*; D018951:Antigens, CD20 / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D002051:Burkitt Lymphoma / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D016499:Radioimmunotherapy; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000637:transplantation; D023041:Xenograft Model Antitumor Assays; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D015021:Yttrium Radioisotopes